难治性胰腺癌的治疗。“2011年美国临床肿瘤学会胃肠癌研讨会”亮点。美国加利福尼亚州旧金山。2011年1月20 - 22日。
Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
作者信息
Makrilia Nektaria, Syrigos Konstantinos N, Saif Muhammad Wasif
机构信息
Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School. Athens, Greece.
出版信息
JOP. 2011 Mar 9;12(2):110-3.
While gemcitabine-based regimens are currently accepted as the standard first-line treatment of patients with locally advanced or metastatic pancreatic adenocarcinoma, there is no consensus regarding treatment in the second-line setting. This review is an update from the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, as these were presented in Abstracts #237 and #272 of the meeting.
虽然基于吉西他滨的治疗方案目前被公认为局部晚期或转移性胰腺腺癌患者的标准一线治疗方案，但对于二线治疗方案尚无共识。本综述是对2011年美国临床肿瘤学会（ASCO）胃肠道癌症研讨会的更新，内容涉及难治性胰腺癌治疗的最新进展，这些进展在会议的摘要#237和#272中有所介绍。
Zotero 插件